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Abstract
Epidemiological evidence link certain chronic bacterial infections to a higher risk of 
cancer development. Induction of an inflammatory circuit and the accumulation of 
genomic instability are considered mechanisms by which bacteria contribute to malig-
nant transformation. Whether production of toxins, that directly induce DNA damage, 
enhances the tumor promoting effects of chronic inflammation is still unknown. This 
thesis investigates the role of the cytolethal distending toxin (CDT), the first bacte-
rial genotoxin identified, in carcinogenesis. We have studied the cellular responses 
to acute and chronic CDT intoxication, as well as the toxin production and secretion 
during bacterial infection.
Acute CDT intoxication triggers the activation of the DNA damage response and in-
duction of survival signals in the target cells, which may favor cancer growth. Through 
a screening of a Saccharomyces cerevisiae library, we identified 78 genes whose 
deletion confers hypersensitivity to CDT exposure (paper I). Bioinformatics analysis 
revealed that DNA repair and endocytosis were the two most represented signaling 
pathways among the genes identified in the screening. We further demonstrated that 
in response to DNA damage, the flap-endonuclease 1 (FEN1) regulated the RHOA-
dependent activation of the actin cytoskeleton and cell survival via the ROCK and 
MAPK p38 kinases, respectively, revealing a complex and previously unrecognized 
crosstalk between DNA damage, cell survival and cytoskeleton dynamics.
As chronic exposure to DNA damaging agents is a well-characterized risk for can-
cer development, we assessed the effects of chronic CDT exposure in vitro (paper 
II). Cells grown for more than six months in the presence of sub-lethal toxin doses 
showed an altered DNA damage response, genomic instability, and acquisition of sev-
eral hallmarks of tumor progression, such as enhanced oxidative stress and capacity 
of anchorage independent growth. Cell survival of the chronically intoxicated cells 
was dependent on sustained activation of the MAPK p38 pathway. To dissect the role 
of CDT in tumor development in vivo, we produced a Salmonella typhimurium strain 
that encode for the Salmonella typhi CDT-like toxin, known as typhoid toxin (TT). As 
control, we used an isogenic strain carrying an inactive toxin. Both strains success-
fully infected the immunocompetent sv129 mice for more than 2 months, however 
only the bacteria expressing the active genotoxin caused an enhanced inflammation 
in liver and spleen.
To understand how this potential bacterial carcinogen is delivered to the target cells, 
we studied the secretion of the Salmonella TT (paper III). We demonstrated that TT 
is secreted from the bacterium via outer membrane vesicles (OMVs). These vesicles 
are further released into the extracellular environment via an exocytosis-like process. 
The paracrine internalization of TT-loaded OMVs by bystander cells was dependent 
on dynamin-1-mediated endocytosis.
Taken together, our studies contribute to elucidate the survival strategy of cancer cells 
in response to CDT, its role in cancer progression and its secreting mechanisms.
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 Numerous evidence link chronic 
bacterial infections to cancer. The human 
bacterium H. pylori was found to cause peptic 
ulcers and to predispose individuals to gastric carcino-
mas, while chronic carriers of Salmonella enterica serovar 
Typhi are at higher risk of liver cancer. More recently, certain 
commensal bacteria of the intestine were shown to contribute 
to inflammatory bowel disease (IBD), a condition that predis-
pose to colorectal adenocarcinomas.
This work aims to dissect the molecular mechanisms un-
derling bacterial-induced carcinogenesis. Particularly, we 
presents studies on a bacterial toxin secreted by several 
Gram-negative pathogens, which presents potential 
carcinogenic characteristic.
Objectives
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1 A BACTERIAL GENOTOXIN
The repertoire of bacterial toxins comprises more then 300 members, including natural variants, isoforms and 
seriotypes. Toxins exert a myriad of functions, hijacking the 
cellular machinery of the host to help the pathogen to establish a 
successful infection. 
Almost all bacterial toxins target the plasma membrane or 
cytosolic molecules, with the exception of two: Colibactin and 
Cytolethal Distending Toxins (CDTs). These toxins enter the 
nucleus of target cells to cause DNA damage, and due to their 
characteristics, Colibactin and CDTs are the only two “bacterial 
genotoxins” described1.
This thesis presents three studies on the biology of CDTs. 
We characterized the cellular response that follows acute CDT 
intoxication (paper I), CDTs carcinogenic properties in vitro and 
in vivo (paper II and preliminary data) and CDT expression and 
secretion from the cancer-associated pathogen Salmonella 
enterica (paper III).
Structure of Cytolethal Distending Toxins
Bacterial toxins are secreted from the bacterium in the 
extracellular environment, from where they bind to the membrane 
of target cells and triggers their active endocytosis. To exert this 
function, toxins present a conserved organization: the A and B 
domains (Box.1). A-domains are the catalytic subunits of toxins, 
while B-domains are “assistant” that mediate the toxin binding 
and internalization. Bacterial toxins can be formed by different 
stoichiometry of A and B domains. Diphtheria Toxin has one 
catalytic and one binding domain (A-B)2, Cholera Toxin has five 
identical B domains (A-B5)3,4, and Anthrax Toxin has two distinct 
catalytic domains (A2-B)4.
The Cytolethal Dystending Toxins (CDTs) is a family of toxins 
produced by Gram-negative bacteria, notably Escherichia 
coli5,6, Aggregatibacter actinomycetemcomitans7, Haemophilus 
BOX.1: Bacte-
rial toxins have 
A- and B-domains 
that exert differ-
ent functions: 
A-domais target 
a component of 
the cell, while B-
domains mediate 
receptor binding 
and internalization.
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Table.1: List of 
Gram-negative 
bacteria found to 
encode for CDT 
genes. In red: hu-
man pathogens.
ducreyi8, Shigella spp.9, Campylobacter spp.10, Helicobacter 
spp.11, and Salmonella enterica serovar Typhi12 (Table.1). 
The presence of CDT in pathogens with very different clinical 
outcomes (from gingivitis to typhoid fever) underlines its 
biological relevance, though limited evidence support its role as 
virulence factor during bacterial infection. CDTs are A-B2 toxins 
composed of three subunits: CdtA, CdtB and CdtC (Fig.1a). 
CdtB is the A-domain, while CdtA and CdtC are B-domains. As 
all three subunits are essential to form a fully active toxin, CDTs 
genes are often found in a single, horizontally acquired operon13.
CdtA and CdtC are structurally similar to each other and to 
the ricin toxin B-domain. Ricin is a potent ribosome-inhibitor 
plant toxin, and its B-domain binds to sugar moieties present 
on the surface of cells14. Similar to ricin B-domain, CdtA and 
CdtC binds to polysaccharides on the cellular surface, though 
with different strength and specificity15. Moreover, CdtA and 
CdtC seem to have distinct functions. CdtA presents a patch 
of aromatic amino-acids that tightly binds to glycoproteins and 
glyocosphingolipids15, and when mutated, it abolish CDT toxicity 
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in vitro16 (Box.2). On the other hand, CdtC seems to assist the 
active subunit to correctly internalize in cells and to reach the 
nucleus17. CdtB is structural homologue to mammalian DNase I 
(Fig.2). This class of enzymes breaks the phosphodiester bounds 
of the DNA backbone, triggering a DNA damage response18,19. 
Mutations of the CdtB catalytic domain and the Mg2+ binding 
domain abolish CDTs intoxication19. In absence of CdtA and 
CdtC, ectopic expression of CdtB in yeast, or microinjection 
in HeLa cells, causes DNA damage, arrest and eventually 
apoptosis18,20,21. 
Cellular internalization and effects
Upon binding to a yet unknown cellular receptor, 
CDTs are internalized by endocytosis22 and enters the 
early endosome, from where cargoes can follow different 
pathways: i) be send back at plasma membrane, ii) 
be degraded into lysosomes, and iii) access the Golgi and the 
endoplasmic reticulum (ER). Hemophilus ducrey CDT (HdCDT) 
is internalized in a dynamin-dependent manner, and enters the 
retrograde pathway from the Golgi to the ER compartment23,24. 
The mechanisms by which CDTs are then transported into the 
nucleus remains to be characterized25. To date, most studies 
Fig.1: Crystal structures of canonical CDT (A) and S. typhi Typhoid Toxin (B). Inset: the unique 
disulfide bound of typhoid toxin.
BOX.2: The CdtA 
domain presents 
ten aromatic 
aminoacids that 
mediate binding to 
cellular receptor(s)
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have looked at the mechanisms of CDTs internalization with 
recombinant purified toxins. It is worth notice that CDTs from E. 
coli and C. jejuni were found secreted within vesicles released 
from the bacterial outer membrane, the outer membrane vesicles 
(OMVs)26,27.
Typhoid Toxin is a particular type of CDT
Salmonella typhi encodes for a different version of CDTs, 
named Typhoid Toxin (TT) (Fig.1b). The TT operon is in a region 
of Salmonella chromosome distinct from the pathogenicity islands 
SPI-1 and SPI-2, probably also horizontally acquired. Whole 
genome analysis of Salmonella showed that the TT operon was 
absent in S. bongori and S. enterica serovar Typhimurium12, 
thus making this toxin unique for the human-restricted pathogen 
S. typhi. TT is composed of three subunits: S. typhi CdtB 
(StCdtB), pertussis-like toxin A and pertussis-like toxin B (PltA 
and PltB). PltB functions as B domain, and is assembled in a 
ring-like hexomer that interacts with cellular receptors (Box.3). 
PltA is a functional ADP-ribosylase with high homology to the 
pertussis toxin S1 domain, but its cellular target is unknown12. 
Lastly, StCdtB is a typical cytolethal distending toxin A domain, 
with similar catalytic pockets and mode of action12. TT is the first 
A2B5 toxin described with two distinct A-domains linked together 
via a disulfide bound28(Fig.1b, detail). Mutation in any of the two 
cysteine residues that mediate the bound prevents intoxication of 
cells infected with S. typhi28 but it is dispensable for the assembly 
of the toxin in vitro29.
Fig.2: The binding 
of mammal 
DNAase I to the 
DNA. Inset: the 
catalytic pocket.
BOX.3: PltB forms 
an hexomer plat-
form that interacts 
with PltA.
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In spite the presence of two A-domains, TT seems to rely 
primarily on its DNase activity to exert toxicity. Mice injected with 
the wild-type or the PltA-inactive TT, experience comparable 
loss of weight and death within a week, while StCdtB-inactive TT 
causes no symptoms. Though i.v. injection of TT in C57BL/6 mice 
does not cause fever, the toxin alone is able to reduce peripheral 
blood leukocytes, particularly neutrophils, a characteristic of S. 
typhi infections in humans28.
Since the primary effect of CDT in the target cells is induction 
of DNA damage, I will discuss the DNA damage response, before 
we consider the cellular effects of intoxication and whether CDT 
may contribute to the tumorigenic process.
2 THE DNA DAMAGE RESPONSE
Fig.3: Different 
genotoxin agents 
can cause double 
strand breaks 
(DSBs) to the 
DNA, and the cell 
can repair the 
damage following 
alternative 
pathways.
As insults like oxidative stress, irradiation and other genotoxin agents can threaten genome integrity, multicellular organisms 
has evolved a complex molecular machinery that blocks cellular 
proliferation while try to fix the damage. This complex network is 
called the DNA damage response (DDR). 
CDTs cause DNA damage in both yeast and human cell 
lines21,30 and trigger a DDR similar to that evoked by ionizing 
irradiation (IR), a well-known carcinogen20,31. IR is energy 
transmitted via x- and γ- rays or α- and β-particles, and similar 
to CDTs, causes DNA double-stranded brakes (DSBs)30.DSBs 
can be repaired following three distinct pathways: homologous 
recombination (HR), non-homologous end-joining (NHEJ), and 
alternative NHEJ (alt-NHEJ)(Fig.3).
These three repair mechanisms involve different proteins and 
ensure different degrees of fidelity after the damage is repaired. 
In general, the choice upon which DDR to execute depends on 
the phase of the cell cycle. HR is favored in S/G2 phase, as this 
pathway requires an homologous template from which to copy an 
entirely new DNA fragment32. On the other hand, NHEJ and alt-
NHEJ do not require DNA templates, and are prevalent in G133.
Regardless the pathway, DDR follows three steps: i) sensing 
the presence of damaged DNA, ii) propagate the alarm signals 
and iii) repair the harm. Proteins classified as sensors, mediators 
and effectors accomplish each one of these steps. Importantly, 
mediators also activate different cyclin inhibitors, which block the 
15
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BOX.4: Crystal 
structures of 
PARP1 (top) and 
the Ku/70/Ku80 
complex (bottom) 
bound to DNA
cell cycle progression.
Sensing and repairing the damage
PARP1/2 and Ku70/Ku80 are important sensors of DNA 
damage (Box.4). PARP1 and PARP2 belong to the poly(ADP-
ribose) polymerase (PARP) family, and initiate the homologous 
recombination repair34. Recruitment of PARP1/2 at the site 
of DSBs causes a conformational change that activates its 
enzymatic pocket and attach polyADP-ribose chains (pADPr) on 
target proteins35. The pADPr chains function as a scaffold for 
other DDR proteins. These include: the sensor/mediator MRN 
complex (see below), the cell-cycle regulator TP53 and the 
ataxia telangiectasia mutated protein ATM36. 
The Ku70/Ku80 is a protein dimer with a toroid shape that 
fits into DSBs like a ring around its finger to stabilize its loosing 
ends37. Ku70/Ku80 recruits the DNA-PK catalytic subunit (DNA-
PKcs), a mediator that orchestrates NHEJ38. In summary, 
PARP1/2 and Ku70/Ku80 compete for binding the break, and 
their regulation can influence the choice of the repair39,40.
MRN and the replication protein A (RPA) complexes are also 
considered DNA damage sensors, since they are able to directly 
bind damaged DNA (MRN) or free single strand DNA (ssDNA) 
during replication fork stalk (RPA)41,42. The MRN is a 
heterocomplex composed by the ATPase RAD50, the 
exo-endonucleases MRE11 and NBS1. RAD50 binds 
to DNA ends in its active form (ATP-bound), aggregating 
MRE11 and NBS1 at the site of the damage43. NBS1 has the 
essential task to recruit the mediator ATM, which propagates 
the DDR signal and promotes repair42. The RPA complex is 
composed by RPA1/2/3. RPA binds onto exposed ssDNA and 
signals the presence of a stalked replication fork, leading to the 
recruitment of the mediator ATR41. A schematic representation of 
the DDR that follows DSBs is depicted in Figure 4. 
Following DSBs, ATM phosphorylates the histone 2AX 
(γ-H2AX) which is important in the propagation of the DDR 
signal, and protein necessary for repairing the damage (effector 
proteins, such as CtIP) and inducing cell-cycle arrest (via 
checkpoint kinase 1 and 2 (CHK1 and CHK2)).
Upon ATM-mediated phosphorylation, CtIP recruits BRCA144 
SENSORS
feel the damage
MEDIATORS
propagate the 
signal
EFFECTORS
execute the repair
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Fig.4: Schematic 
representation 
of DNA damage 
response that 
follows DNA 
DSBs.
and leads to an extensive resection of the DNA. RPA1 can now 
feel the ssDNA and execute the Holliday junction together with 
BRCA236. In G1 phase, where sister chromatin is missing, CtIP 
carries on a limited resection (independently from BRCA1) and 
repairs the damage via the alt-NHEJ pathway45.
Additionally to repair, ATM is required to activate CHK2, which 
blocks the cell-cycle progression via the inhibitory phosphorylation 
of CDC25. In G2/M, CDC25 alone can mediate arrest, but for a 
proficient G1/S checkpoint, the activity of TP53 is also required. 
TP53 mediates the transcription of the cycling inhibitor p21, 
which is essential for a prolonged G1 arrest46(Fig.5). 
DDR response in CDT intoxicated cells
Cells intoxicated with CDTs shows a similar DNA damage 
response to that evoked by ionizing radiations, a well know 
carcinogen22, with ATM phosphorylation and the activation of the 
classical DNA damage and checkpoint responses1. The DDR 
signal is further transduced to the cytoplasm via the export of 
the guanine exchange factor NET1 from the nucleus30,47, leading 
to the activation of the small GTPase RHOA30,47,48. From here, 
the NET1-RHOA signal cascade diverges into two different 
CDC25 is a group 
of phosphatases 
required for cyclin-
dependent kinases 
(CDKs) activity.
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Fig.5: ATM 
phosphorylates 
CHK2, leading to 
cell cycle arrest 
in G1/S and 
G2/M (via the 
CHK2-dependent 
phosphorylation 
and inhibition 
of CDC25) and 
sustained G1 
arrest (via the 
TP53-dependent 
transcription of 
the CDK inhibitor 
p21). In cell 
lines carrying an 
inactive TP53, 
CHK2 mediates 
preferentially a G2 
arrest.
pathways. On one side, the kinases ROCK1 and ROCK2 
induce the formation of actin stress fibers; on the other side, the 
phosphorylation of the mitogen activated protein kinases p38 
(MAPKs p38) promote cell survival47. A schematic representation 
of this pathway is depicted in Figure 6.
In cells of epithelial and mesenchymal origin, acute DNA 
damage leads to senescence49, while cells of lymphoid origin 
die of apoptosis31. Interestingly, this cell dependent behavior 
correlates with the activation of the NET1-RHOA pathway.
Understanding the molecular mechanisms by which cells escape 
CDT-dependent apoptosis might shade light on the possible role of 
the toxin as carcinogen. Additionally, as chemotherapeutic drugs 
and irradiation are standard procedures in cancer treatment, 
these studies might help to refine medical interventions.
To further characterize the survival signals triggered by the 
NET1-RHOA axis, in paper I we screened for genes whose 
deletion causes enhanced apoptosis after acute intoxication. To 
this end, we transfected a Saccharomyces cerevisiae mutant 
library that carry single deletions in nonessential genes with 
an expression vector encoding for the CdtB gene under an 
inducible promoter. With this tool, we identified 78 genes whose 
deletion confers hypersensitivity to the toxin. Gene ontology 
analysis identified DDR, and more surprisingly endocytosis, as 
the two most represented pathways among the gene identified 
in the screening. A similar pattern was previously observed in 
yeast screening assessing the hypersensitivity to agents that 
cause DNA DSBs50,51. As our primary interest was the RHOA-
mediated survival, we used bioinformatics to create a network 
of all known RHOA primary and secondary interacting partners, 
and interrogated this database for the presence of gene products 
found in our analysis. The genes encoding for FEN1 and TSG101 
PAPER I
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Fig.6: The NET1-
RHOA dependent 
cell survival 
pathway that 
is activated in 
response to acute 
CDT intoxication.
regulates DDR and endocytosis, respectively, and were further 
validated in mammalian cells. We demonstrated that FEN1, but 
not TSG101, regulated RHOA activation, actin stress fibers, 
MAPK p38 phosphorylation and cell survival in response to DNA 
damage.
The flap-endonucleases 1 (FEN1) is a multifunctional enzyme 
with important roles for the normal DNA metabolism52-55. FEN1 
resolves Okazaki fragments during DNA replication and it 
is required for functional base-excision repair (BER)56. This 
protein is subjected to different post-translational modification 
events, including phosphorylation by CDK1 and CDK257, which 
increases during S-phase and enhances FEN1 activity, leading 
to S to G2 transition. Mutations of one of FEN1 phosphorylation 
sites (S187) prolong the S-phase in the normal course of the cell 
cycle58. Since FEN1 plays a role in HR59, its expression is further 
up-regulated following DNA DSBs in yeast 54.
Our work shows for the first time a role of FEN1 in the activation 
of the RHOA survival pathway that follows DNA DSBs. In line 
with our findings, MEFs with a partially inactive FEN1 are also 
more susceptible to apoptosis following UV irradiation compare 
to wild-type cells60.
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How can FEN1 control RHOA activity? FEN1 was found to 
interact with the RHOA-regulating protein ARHGDIA in a yeast 
two-hybrid screening65. The nature of this interaction and its 
functionality has not been explored yet in mammal cells. As 
ARHGDIA maintains RHOA in an inactive state66, it is feasible 
that the increased transcription of FEN1 following DSBs might 
be necessary to sequester ARHGDIA. Interestingly, other DDR 
proteins were found to exert pro-survival function via their 
interaction with cytoplasmic partners. The DDR sensor DNA-PK 
can localize in lipid raft microdomains of the plasma membrane61, 
where it phosphorylates AKT62, a pro-survival factor for cancer 
cells63. Similarly, the Ku70/Ku80 protects cells from apoptosis 
suppressing BAX translocation in the mitochondria64. To date 
there are no report on the presence of FEN1 in the cellular 
cytoplasm, however, a new truncated FEN1 isoform (generated 
by alternative translation) was recently found in mitochondria67.
Ultimately, FEN1 could be important for the activation and 
translocation of NET1, the nucleotide exchange factor that 
activates RHOA after CDT intoxication, or for the activation of 
other components of HR that mediate RHOA activation.
So far I described the importance of survival signals that 
play a key role in tumorigensis, but alone are not sufficient for 
cancer initiation/progression. Cancer cells not only have to avoid 
DNA-damage dependent cell death, but will have to sustain 
their independent proliferation, become immortal, promote 
angiogenesis, reprogram their metabolisms and metastasize68. 
The magnitude of genetic rearrangement necessary to accomplish 
these tasks is achieved via acquisition of genomic instability.
Genomic instability (GI) is a status in which cells experience genetic rearrangements, which comprises generation of 
new point mutations, small deletions/insertions of DNA sequences 
and gross chromosomal translocations69. Epidemiological and 
experimental evidence indicate that GI is a driving force of 
cancer70.
How does GI occur?
GI occurs when a chronic, sub-lethal dose of DNA breaks 
exceed the capacity of the DNA damage response (DDR) to 
properly repair the damage. The source of DNA damage can 
be endogenous like a sub-optimal DDR, oncogene activation 
or oxidative stress; or exogenous, like chemicals, irradiation, or 
bacterial toxins.
A. Sub-optimal DNA damage response
In hereditary cancer, the origin of GI is attributed to mutations 
in “caretakers genes”, responsible for the correct DNA repair 
pathway and the mitotic checkpoint46,71. For example, germ-
line mutations in the DNA mismatched repair protein MSH272, 
or DNA base excision repair gene MYH73 are associated with 
a higher risk of colon adenomas in humans. Mutations in other 
DNA repair genes, like breast cancer susceptibility 1 and 2 
(BRCA1/2), RAD50, Nijmegen breakage syndrome 1 (NBS1), 
bloom syndrome helicase (BML), Fanconi anaemia genes, 
and nucleotide-excision repair genes can all predispose to 
various diseases and tumors, notably leukemia, lymphomas, 
breast, ovarian and skin cancers74-77As these genes encode for 
proteins with not-redundant roles, their inactivation irreversibly 
compromises both the repair of DNA and the activation of the 
checkpoint response.
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B. Oncogene activation
Inactivation of caretakers genes do not seem the main 
mechanism for acquisition of GI in sporadic cancer70, suggesting 
the existence of alternative events, such as oncogene-induced 
replicative stress78.
Gross chromosomal abnormalities are seen in murine 
fibroblasts NIH 3T3 transfected with HRAS79. The same is true 
for the immortal rat fibroblasts Rat1A over-expressing c-MYC, 
which present aneuploidy and have dicentric chromosomes80,81. 
Further more, a brief over-expression of c-MYC can increase the 
level of reactive oxygen species and mitigate the TP53 activity 
in primary human fibroblasts82, which can become aneuploid80.
C. Reactive oxygen species (ROS)
Another source of GI might be the exposure of reactive 
oxygen species or reactive nitrogen intermediates (ROS and 
RNI) beyond their physiological levels83. Oxidative DNA damage 
is detected by the presence of 8-Oxo-2’-deoxyguanosine 
(8-oxodG), an oxidated product of the base guanosine. This 
oxidation further leads to mismatch 8-oxodG with adenine, 
resulting in a G->T or A->C substitutions84. Due to its genotoxic 
activity, ROS might facilitate cellular transformation. Mice 
embryo fibroblasts (MEFs) briefly treated with exogenous ROS 
have enhanced transformation capacity in vitro and in vivo85, 
and genetic alterations that enhance ROS production promote 
malignant transformation in other cell models86-88.
Signs of ROS-damage are also seen in inflammatory diseases 
that precede cancer. Livers of chronic hepatitis patients present 
elevated levels of 8-oxodG compared to matching controls89 and 
transgenic mice with chronic hepatitis progressively accumulate 
8-oxodG in their hepatocytes90. A persistent oxidative stress 
may be responsible for the genomic instability seen in primary 
Fig.7: Different 
mechanisms 
lead to genomic 
instability in 
hereditary and 
sporadic cancers
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bone marrow cell cultures91, and high level of mitochondrial-
produced ROS triggers GI in lymphomas cell lines92. Particularly 
in lymphomas, GI was associated with an increased number of 
drug-resistant cells92. 
Other examples come from oncogenic viruses. The 
chromosomal rearrangements observed in primary B-cells 
infected with the transforming Epstein-Barr Virus (EBV)93 may be 
ROS-dependent, as the use of scavengers in EBV-transformed 
lymphocytes reduces DNA damage94 and restores telomers 
function271.
As I will describe in Chapter 4, also chronic bacterial infections 
promote ROS production by immune cells at the site of the 
infection, as means of anti-bactericidal activity.
GI can activate oncogenes
The random DNA mutations caused by GI can hit oncogenes 
that control cellular proliferation. RAS, CTNNB1 (catenin β1), 
and c-MYC are frequently mutated in human tumors, and their 
aberrant activation has been proven to be a driving force for 
tumorigenesis.
Somatic activation of KRAS promotes lung cancer in transgenic 
mice95, and when genetically activated in the intestine, β-catenin 
promotes spontaneous polyposis and adenomas96. Over-
expression of c-MYC in the hematopoietic lineage predispose 
mice to highly penetrant lymphomas and leukemias97, and c-MYC 
inactivation causes tumor remission98. Oncogenes can also work 
together to facilitate tumorigenesis. Co-expression of RAS and 
c-MYC can more easily transform mouse NIH 3T3 fibroblasts 
in vitro than when used individually272, and the same oncogene 
combination greatly enhances tumor susceptibility in mice99. 
Ultimately, the success of oncogene-inhibitory drugs that target 
BCR-ABL, c-KIT and EGFR underlines the key role of oncogenes 
in cancer development and their therapeutic potential.
Human cells were proven more resistant than mice or chicken 
to transformation by expression of single or multiple oncogenes, 
arguing against the role of sole oncogenes in the development 
of human cancers273. GI must therefore subvert also additional 
mechanisms that block tumor development.
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GI can suppress the tumorigenic barrier
The presence of moles on our skin indicates that sporadic 
proliferation of cells can occur rather frequently in humans100. As 
these melanocytes will rarely become a skin cancer, mammals 
must have evolved mechanisms that efficiently counteract 
oncogene-triggered tumors. When human primary fibroblasts are 
infected with oncoviruses, a rapid cellular proliferation is shortly 
followed by permanent cell-cycle arrest, called senescence101, 
while introduction of c-MYC in immortal rat fibroblasts causes 
massive apoptosis102. The activation of these two responses 
is defined as tumorigenic barriers, a defense mechanisms 
against de-regulated proliferation. Activation of the tumorigenic 
barrier reduces cellular transformation in vitro and prevents pre-
carcinogenic lesions to evolve into fully established cancers in 
vivo103,104.
Senescence is an irreversible cell-cycle arrest, characterized by 
cellular distention and activation of markers like β-galactosidase 
both in vitro and in vivo105. Apoptosis is a programmed cell death 
that, at least in response to stress signals caused by hyper-
proliferation, is characterized by cytochrome-c release and 
caspases activation106. 
In the contest of cancer development, the tumorigenic barrier 
can be activated by oncogene-induced replicative stress78,107. 
Replicative stress is caused by the over-expression of 
oncogenes like c-MYC and HRAS that cause the simultaneous 
firing of the same DNA origin of replication, causing an increase 
of fork stalling108,109. The consequent activation of DDR triggers 
a signal cascade that leads to a TP53-mediated activation of 
the tumorigenic barrier110. Signs of oncogene-induced DDR 
and TP53 activation also can be observed in pre-cancerous 
lesions in individuals. Analysis on specimens from urinary 
bladder, breast, lung, skin and colon carcinoma revealed that 
pre-carcinogenic lesions are characterized by DDR markers, 
like the phosphorylation of ATM, CHK2 and H2AX. The effective 
DDR leads to TP53 activation, indicating a fully active counter-
response to the incipient neoplasia, where proliferative markers 
like Ki67 are completely absent103,111(Fig.8).
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TP53 is a master regulator of the tumorigenic barrier
The tumor suppressor TP53 plays a key role in activation 
of the tumorigenic barrier106. TP53 is a transcription factors of 
a multitude of genes112, including the pro-apoptotic PUMA, 
NOXA, BID and BAX113. Following stress signals, like oncogenes 
activation or exogenous DNA damage, TP53 accumulates in the 
cellular nucleus, where it facilitates DNA repair and cell-cycle 
regulation. Nevertheless, in response to overwhelming stimuli, 
TP53 tips the balance towards senescence or apoptosis, thus 
preventing cellular transformation110. Due to its key role as tumor-
suppressor, TP53 is frequently mutated in human cancer274, and 
mice that lack one or two copies of the gene are more susceptible to 
spontaneous and environmentally induced tumors114-116. Though 
TP53 mediates both senescence and apoptosis in normal cells, 
it remains unclear what determines the choice between these 
pathways107, and which response is primarily responsible for 
tumor prevention.
A. TP53-mediated apoptosis
Numerous line of evidence indicates that apoptosis is an 
effective regulator of the tumorigenic barrier. The transformation 
Fig.8: Schematic 
representation of 
the tumorigenic 
barrier. In normal 
tissues, cell 
proliferation is 
stable and there 
are no signs of 
damaged DNA 
and activation of 
DDR. As genomic 
instability begins, 
pre-carcinogenic 
lesions display an 
active DDR that 
blocks cellular 
proliferation via 
senescence 
or apoptosis. 
In cancer, the 
DDR that leads 
to senescence 
and apoptosis 
is suboptimal, 
thus allowing 
abnormal cellular 
proliferation.
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capacity of E1A oncogene in mouse embryo fibroblasts (MEFs) 
is partially blocked by extensive apoptosis mediated by TP53117. 
MEFs deficient in BAX, are rescued from E1A-dependent cell 
death and more easily transformed in vitro and in vivo118. In a 
mouse model of c-MYC driven pancreatic cancer, the oncogene 
activity in adult β-cells induces tissue proliferation accompanied 
by overwhelming apoptosis102. The apoptosis was mediated by 
the pro-apoptotic TP53 target gene Bcl-xL. Mice with genetically 
inactive BAX or PUMA have similar tumor incidence to TP53-/- 
genotype110,118,119.
B.TP53-mediated senescence
The extensive use of cancer cell lines to study cellular 
biology have brought to the erroneous idea that when DNA 
damage is not reparable, cells inevitably enters apoptosis. 
Most studies120 in primary human fibroblasts show that over-
expression of oncogenes like MYC, HRAS, BRAF and E2F1 
leads to a permanent cell-cycle arrest, with all the traits of cellular 
senescence101,121-124. Mice data support the role of senescence 
as tumorigenic barrier. In a murine model for hepatobiliary 
carcinoma, genetically restoration of wt-TP53 causes tumor 
remission via senescence125. Senescent hepatocytes seem 
to trigger their clearance by secreting cytokines that attracts 
phagocytes. In the human colon, senescent rather than apoptotic 
cells are found in adenomas, the pre-carcinogenic lesions that 
precede carcinomas104. 
As both cellular senescence or apoptosis have been seen in 
different tumorigenic studies100,109,126-128, the activation of either 
responses seems to be tissue and model dependent, thus both 
should be assessed in every carcinogenic model.
Genomic instability is not the only enabling hallmark of cancer. 
To stand DNA damage and survive, pre-malignant cells may 
need the help of external, pro-survival stimuli. As I will describe 
in the following paragraph, pro-survival signals can come from 
an inflammatory response. It is noteworthy that such responses 
can be triggered by chemicals, genetic predisposition or bacterial 
infections.
BAX is the main 
mediator of 
TP53-dependent 
apoptosis.
Epidemiological evidence indicates that some type of chronic inflammatory syndromes predispose to cancer in humans. 
Patients suffering from inflammatory bowel disease (IBD) such 
as Crohn’s and ulcerative colitis, are at high risk of intestinal 
tumors129, while cirrhosis and hepatitis strongly associate with 
hepatocellular carcinoma130. 
Chronic inflammation and cancer were proved to be causally 
linked in animal models and interventional studies. Chronic 
ulcerative colitis can be induced in mice with a single dose of 
the genotoxin agent azoxymethane (AOM) followed by repeated 
administration of the pro-inflammatory chemical dextran sulfate 
sodium (DSS)131(Box.5). After 10 weeks, the mouse intestine 
is severely inflamed with sporadic episodes of colorectal 
adenocarcinoma (CAC), characterized by classical markers: 
β-catenin nuclear translocation and c-MYC up-regulation131,132. In 
this model, the small intestine had only minor villi neoplasia, and 
the colon is confirmed to be the main area for cancer onset of the 
entire gastrointestinal tract.
A major player in inflammation-driven carcinogenesis is 
the family of nuclear factors-κB (NF-κB)(Fig.9). NF-κB are 
transcription factors that assemble in heterodimers and mediate 
the expression of pro-inflammatory genes133. In absence of 
signals, NF-κBs are prevented from entering the nucleus by 
inhibitors of NF-κB (IκBs). In response to dangerous stimuli, 
like cytokines, bacterial and viral products134, cellular receptor 
activates the IκBs kinases (IKKs), which phosphorylate IκBs and 
target them for degradation. Released from their inhibitors, NF-
κBs can now enter the nucleus and activate the transcription of 
pro-inflammatory cytokines like TNF-α, IL-6, IL-23 and COX-2. 
The IKKs -> NF-κB activation is the canonical pathway of the 
inflammatory response.
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BOX.5: Mice 
model for 
induction of
ulcerative colitis 
and colorectal 
adenocarcinoma
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There are three different IKKs: IKK-α, IKK-β and IKK-γ. IKK-α 
and -β are kinases that targets IkBs, while IKK-γ is a regulatory 
subunit essential for these two kinases activity135.
Oncogenes like CCNDBP1 (Cyclin D1) and c-MYC are 
transcription targets of NF-κB, together with anti-apoptotic Bcl-
XL and IAP-1. Due to its pro-survival and proliferation activity, 
the NF-κB pathway is essential for mouse embryogenesis and 
wound healing136.
Relevant for this discussion, bacteria can activate NF-κB 
signaling via Pattern Recognition Receptors (PRRs). PRRs are 
specialized sensors of numerous pathogen products that transmit 
an alert signal to the cells137. MyD88 is the adaptor protein that 
specifically links PRRs to IKKs138, and dendritic cells depleted for 
MyD88 fail to activate NF-kB after bacteria exposure139. 
Colorectal cancer
In animal models of ulcerative colitis, the inhibition of NF-
κB activity via the use of anti-IKKs drugs140, or antisense-RNA 
therapy141 blocks the secretion of the pro-inflammatory TNF-α, 
IL-1 and IL-6 in the colon. This inhibition reduces chronic 
inflammation and CAC development. Other studies indicate that 
NF-kB exerts a pro-survival function on pre-carcinogenic cells. 
Mice with cell-specific IKK-β knockout in intestinal epithelial cells 
IKK-γ knockout 
mice die at E.12.5-
13 due to sever 
liver damage 
caused by apopto-
sis275.
Fig.9: The 
transcription 
factor NF-kB 
is activated via 
different pathways, 
mainly TNF- 
and pathogen 
mediated
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(IECs) (IKK-β-/∆ IECs) develop less adenomas when put on a CAC 
regime (AOM + DSS) compare to IKK-β-/+IECs litter-mates132. In 
this model, IKK-β-/∆ IECs mice had higher IECs apoptosis, though 
cytokines and inflammation were comparable to controls. When 
IKK-β was depleted in the myeloid lineage in the same model, 
proliferative factors like IL-6 and IL-8 were reduced in the colon. 
These data indicates a dual role of NF-κB in colon cancer: in 
enterocyte NF-κB plays a pro-survival role, while macrophages 
of the lamina-propria are responsible for secretion of proliferative 
factors (Box.6).
Bacteria can contributes to fuel the pro-inflammatory signaling 
that precede adenomas. Deficiency in MyD88 (MyD88-/-) 
increases the survival of mice genetically predispose to polyposis 
and adenomas143. The reduced number and size of polyps 
detected was associated with the reduced expression of pro-
tumorigenic cytokines like TNF-α, IL-1β and COX-2. The MyD88-
/- background also prevents adenomas in the AOM+DSS model of 
ulcerative colitis143. In another model of genetically induced CAC 
with ulcerative colitis (rag2-/- x T-bet-/-, TRUC)144 the mucus layer 
in the intestine is thinner compare to controls. This contributed 
to chronic inflammation, transcription of inflammatory cytokines, 
ROS production and 8-oxodG DNA damage in intestinal epithelial 
cells. Finally, the administration of antibiotic reduces the number 
of tumorigenic and pre-tumorigenic lesions145, underling the 
relevance of bacterial-induced inflammation in cancer onset.
Certain group of commensal bacteria may exacerbate 
chronic inflammation. The microbiota composition of TRUC 
mice was found to be different from the one of matched controls 
(rag2-/-)146. TRUC colitis could then be transmitted to WT mice 
following perinatal exposure to a TRUC-mother144. Further test 
on the microbiota composition pointed to the Gram-negative, 
anaerobic K. pneumoniae and P. mirabilis as responsible for 
the transmissible colitis146. An ever increasing body of evidence 
points to the colonization with different commensal bacteria as 
driving force for life-long diseases, like colitis, allergies, obesity, 
malnutrition and cancer147.
H. pylori is a bacterium that colonize the stomach of half of 
the world population, and some strains increases the risk of 
BOX.6: In colorec-
tal cancer, NF-kB 
plays a double 
role: in epithelial 
cells, mediate cell 
survival, while in 
immune cells is 
required for the 
secretion of prolif-
erative factors.
Reduced mucus 
layer is found also 
in the colon of IBD 
patients142.
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gastritis and stomach cancer148. Overnight incubation of H. pylori 
enhances ROS levels and 8-oxoG damage in gastric epithelial cell 
lines276. High ROS levels are also observed in stomach of patients 
suffering from H. pylori-induced gastritis, and antibiotic treatment 
reduces ROS in the same patients277. BigBlue® mice infected for 
6 months with H. pylori have in average 4-fold increase in gene 
mutations compare to uninfected mice149. As these mutations 
were mainly transversions, this H. pylori-associated genomic 
instability was attributed to the oxidative stress caused by the 
host inflammatory cells.
The bacterium Bacteroides fragilis is a habitant of the human 
colon. Enterotoxigenic strains of B. fragilis (ETBF) encode for 
B. fragilis toxin (BFT) that causes inflammatory diarrhea in 
some individuals, while asymptomatically colonize a portion 
of the human population. In APCmin mice, BFT-producing B. 
fragilis triggers colitis and induces more colonic tumors compare 
to BFT-negative bacterial. The toxin was responsible for the 
activation of STAT3, a transcription factor that, similarly to NF-
kB, mediate immune response. STAT3 was found responsible 
for the recruitment of pro-inflammatory T helper type 17 (Th17) 
in the colon, which secretes the pro-inflammatory cytokine IL-
17. Antibody blockage of IL-17 inhibits colitis and hyperplasia in 
the mice. These data indicates the active role of the adaptive 
immunity in fueling the tumorigenic process150.
Liver cancer
Differently from CAC, the role of NF-κB in development of 
hepatobiliary carcinoma is less understood. Patients suffering 
from viral-dependent or -independent hepatitis present higher 
nuclear localization of NF-κB compare to normal livers151,152. This, 
however, is not conclusive for its role in tumorigenesis. In models 
where hepatocellular carcinoma (HCC) is triggered by low-grade 
hepatitis (due to biliary tract disfunction (mdr2-/-)153 or hepatocyte 
apoptosis (LTα:βhep)154 in mice) tumors incidence is reduced 
by genetic impairment of NF-κB activity in hepatocytes154,155. 
In both models, NF-kB prevents apoptosis via transcription of 
pro-survival genes (A1/Bfl1 and GADD45beta) thus favoring 
tumor progression. The NF-κB anti-apoptotic activity seems to 
be essential during late stage of tumor development155, rather 
APC  is a gene 
commonly mu-
tated in familial 
denomatous 
polyposis (FAP). 
The APCmin mice 
carry a truncated 
version of the 
APC protein and 
develop up to 100 
polyps in small 
intestine and colon 
tumors.
NF-κB as 
tumor 
promoter
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than in the initiation steps 132. Similarly to the CAC model, the 
fundamental inflammatory process in mdr2-/- mice is maintained 
after hepatocyte-specific NF-kB inactivation. This points to 
myeloid cells as the main source of inflammatory cytokines that 
maintain the inflammatory environment necessary to fuel tumor 
progression.
On the other hand, NF-κB activity is lower in liver metastasis 
than in primary tumors in patients, favoring a scenario where NF-
κB function as tumor suppressor151. Consistently, inactivation of 
NF-κB in IKK-γ knockout adult mice promotes development of 
spontaneous hepatitis, fibrosis, and HCC156, and mice deficient 
for IKK-β in hepatocytes (IKK-β-/∆ hep) are more susceptible to HCC 
after administration of the mutagen diethylnitrosamine (DEN). 
How to explain these conflicting data? In the latest models, 
NF-κB maintains DEN-mutated cells alive and prevents the 
compensatory proliferation that follows apoptosis, thus limiting the 
expansion of these cells. This is consistent with the observation 
that hepatectomy, following DEN-treatment, also promotes HCC 
via the induction of cell proliferation necessary to regenerate the 
tissue157
NF-κB can thus function as either promoter or suppressor of 
tumorigenesis in the liver, and its role in the contest of chronic 
bacterial infections has not yet been elucidated.
Fig.10: NF-kB can have both pro-tumorigenic and anti-tumorigenic functions 
in liver. In hepatocytes, NF-kB is a potent anti-apoptotic transcription factor. 
In some instances, this effect is detrimental because supports survival of pre-
malignant cells (A). In other contexts, the survival properties of NF-kB avoid 
compensatory proliferation, thus preventing expansion of mutated cells that 
may be tumorigenic (B).
NF-κB as 
tumor 
suppressor
(Fig. ten).
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So far, I explained how GI and chronic inflammation 
favor tumorigenesis. We saw that bacteria can trigger pro-
tumorigenic inflammatory response via PRRs and the NF-
kB pathway, and favor GI via production of ROS. In the 
next chapter, I will describe how bacteria can directly cause 
DNA damage in a ROS-independent manner, focusing on 
the genotoxin CDT.
5 BACTERIAL PRODUCTS MAY DIRECTLY TRIGGER GENOMIC INSTABILITY
Beside production of ROS, associated with chronic inflammation, some bacterial infections might contribute 
to induction of genomic instability via alternative mechanisms. 
Indeed, mouse gastric epithelial cells infected with H. pylori shows 
signs of DNA damage response that could not be prevented by 
ROS scavengers, or by the combined deletion of genes encoding 
for nitric oxide synthase (iNOS) and NADPH oxidase 2 (NOX2)158. 
Additionally, H. pylori can down-regulate the expression of 
proteins responsible for the mismatch repair (MMR) pathway 
in vitro159 and to some extent in vivo160, thus compromising the 
cellular DDR. Interestingly, the gastric epithelium of patients 
with stomach cancer shows high-rate of microsatellite instability 
(MSI)161, a form of GI that arise from a dysfunctional MMR162. 
H. pylori was found more frequently in gastric tumors with MSI 
compare to tumors without MSI163. Today, the protein(s) or the 
metabolite(s) responsible for the induction of ROS-independent 
DNA damage or the down-regulation of the MMR proteins remain 
unknown.
Other pathogens, like Neisseria gonorrhoeae278 and 
Pseudomonas aeruginosa164, have been shown to induce a 
certain degree of DNA damage in vitro, but their mechanism of 
action remains unclear. 
A mechanism for the promotion of GI during chronic bacterial 
infection may be the production of toxins that directly cause DNA 
damage. Today, the only characterized bacterial genotoxins 
are Colibactin and CDTs 1, however their contribution to 
carcinogenesis has not been fully assessed.
In paper II, we studied whether chronic intoxication with 
CDT promotes genomic instability. To this end, we have grown 
different cell lines of epithelial and mesenchymal origin in the 
presence of sub-lethal doses of the toxin, which did not induce an 
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acute cell cycle arrest, but still caused DNA damage as assessed 
by formation of micronuclei already at 2 days post intoxication. 
Traits of genomic instability were maintained for one week, and 
persisted in the sub-lines selected in the presence of the toxin up 
to 220 days. No detectable changes were seen in cells selected 
with a mutant inactive toxin at comparable density and passages 
throughout two independent experiments. 
Long-term exposure to sub-lethal CDT-doses leaded to a time 
dependent increase in mutation frequency of a reporter gene 
of the immortal rat fibroblasts BigBlue®. Mutations were mainly 
transversions, while transitions and insertion/deletions were 
less frequent. This effect was associated with higher frequency 
in nuclear abnormalities and chromosomal aberrations. 
Similar effects were also observed after short-term infection of 
mammalian cells with E. coli strains producing Colibactin, the 
other known bacterial genotoxin165. 
What could promote the proliferation and survival of our 
cells, in spite of the marked GI induced by CDT? As previously 
discussed (Chapter 3), one mechanism is the overcoming of the 
tumorigenic barrier, which can be achieved by impairment of the 
DDR. Indeed, we could demonstrate that cells selected in the 
presence of the active toxin showed a significant reduction in 
sensing the DNA damage, followed by a reduced activation of 
the downstream checkpoint. Additionally, in our experiment, GI 
resulted in the production of a heterogeneous population of cells. 
This favored the insurgence of cells able to survive in absence 
of anchorage, as we detected more colonies in the soft-agar 
experiment in cells exposed to the wild type CDT compare to 
mutant toxin.
MAPKs p38 and cell survival
The activity of MAPKs p38 plays a key role in cell survival 
following CDT exposure both in acute and chronic intoxication 
(papers I and II). MAPKs p38 is a group of highly related enzymes 
encoded by four different genes in human, corresponding 
to isoform p38-α, -β -γ and -∂. All these isoforms can be 
phosphorylated in response to stress, like DNA and oxidative 
damage, hypoxia, ischemia and cytokines166. 
While it is generally accepted that MAPKs p38 function as 
PAPER II
Transversions 
are exchange of a 
purine for a purine 
or a pyrimidine 
for a pyrimidine, 
while transitions 
are exchange 
of a purine for a 
pyrimidine or a 
pyrimidine for a 
purine.
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tumor-suppressor in normal cells 167,168, in cancer its role is less 
understood166. In paper I and II, and in previous work from our 
laboratory47, MAPKs p38 protects cells from apoptosis, thus being 
pro-tumorigenic. In line with these evidence, epidemiological 
studies link high levels of phospho-MAPKs p38 with a more 
malignant phenotype, in lung, thyroid and breast cancer, glioma, 
follicular lymphomas, and neck squamous cell carcinomas169-174.
In paper II, it is worth notice that though the relative levels of 
phospho-MAPKs p38 were higher in these cells, the total amount 
of MAPKs p38 was actually lower compared to controls. This 
might suggest a selective pressure for reducing the total amount 
of this kinase. Other studies have tried to assess the role of 
MAPKs p38 following DNA damage. Particularly, the ability of 
ionizing radiation to regulate MAPK p38 activity in cancer cells 
appears to be highly variable, from no activation175, to weak and 
strong activation176,177. In lung, head and neck cancer cell lines, 
an elevated basal level of phospho-MAPKs p38 correlates with 
resistance to the DNA damaging drug cisplain178. 
We also report that increased level of ROS is another 
carcinogenic traits of CDT-mediated transformation. High ROS 
accumulation is a trait of some cancer cells, and might further 
contribute to overcome the tumorigenic barrier. There seems to 
be a relationship between MAPKs p38 pathway and endogenous 
ROS levels in normal and cancer cells. ROS can activate MAPKs 
p38 in ovarian epithelial tumors179 and, in turns, MAPKs p38 
prevent accumulation of ROS in a breast cancer mice model180. 
Immortalized mouse embryo fibroblasts (MEFs) deficient for 
MAPK p38-α are more easily transformed by HRAS than wild 
type cells, and this transformation seems to be mediated mostly 
by the ROS induced by the oncogene181. In the early step of 
transformation, HRAS induces reactive oxygen species that 
can accumulate at high level only when MAPK p38-α is absent. 
Interestingly, cancer cell lines with endogenous high level of ROS 
shows sub-optimal MAPK-p38 activation and increased capacity 
to grown in anchorage-independent manner181. Collectively, 
these data suggest that transformation of immortalized rodent 
cells like NIH3T3 and BigBlue® is prevented by high levels of 
MAPKs p38, and its signal must somehow be finely tuned to 
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allow cellular transformation. 
However, other mechanisms can uncouple ROS from MAPKs 
p38 activation. GSTM1 and GSTM2 are members of the GST 
family, and their over-expression inhibits the oxidative stress-
induced activation of MAPKs p38182,183. The level of mRNA of 
these genes increases with the level of ROS in different cancer 
cells, suggesting that GSTM1/2 protect from MAPKs p38-
dependent apoptosis caused by oxidative stress.
As I discussed above, the carcinogenic process encompasses 
numerous mechanisms, and the enabling cancer hallmarks are 
both GI and pro-carcinogenic inflammation. We have shown 
in paper II that long-term exposure to sub-lethal doses of CDT 
is carcinogenic in vitro. To fully characterize the molecular 
mechanisms by which CDTs contribute to tumorigenesis in vivo, 
we focused on the Salmonella Typhoid Toxin, and developed a 
model of chronic infection in immune competent mice. Salmonella 
was chosen as model bacterium since it is the only CDT-like 
producing pathogen associated with human cancer184-190.
In the next chapter, I will briefly summarized the mechanisms 
of S. enterica pathogenesis and introduce the model we have 
developed.
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Salmonella typhi is a facultative anaerobic, Gram-negative bacterium279 responsible for typhoid fever, an infection 
disease that causes general ill-feeling, abdominal pain and 
temperature, due to a systemic bacterial infection. High fever 
and severe diarrhea might occur during the course of the disease 
if untreated191. Though typhoid fever is rare in the United States 
and Europe, it is endemic in Asia, Africa and South America192 and 
the U.S. Centers for Disease Control estimates at least 22 million 
people affected worldwide and 200.000 death each year280.
The correct designation for Salmonella typhi is “Salmonella 
enterica, enterica subspecies, serovar Typhi”. For simplicity, 
I will use S. enterica to refer to Salmonella enterica, enterica 
subspecies; while S. typhi and S. typhimurium, respectively, will 
be use to indicate the two serovars193-195.
S. enterica pathology
From the prospective of the clinical outcomes caused by 
S. enterica infections, three distinct syndromes have been 
classified: typhoid fever, septicemia and enteritis. Typhoid 
fever is a systemic infection in humans that is caused by the S. 
enterica serovars Typhi, Paratyphi A, Paratyphi B, and Paratyphi 
C. Importantly, each one of these bacteria is a strict human or 
high-primate pathogen, as none of these serovars are able to 
infect other mammalians196. 
The characterization of the pathology of S. typhi infection in 
humans comes from pioneering studies in the 1970s where the 
pathogen was administered to consensus volunteers197(Fig.11). In 
one of these largest studies, Hornick et. al. infected approximately 
200 individuals191, with doses ranging from 104 to 109 bacteria. 
Fever was the first clear outcome, after a median incubation 
time of 5-9 days, depending on the load administrated. Some 
individuals manifested constipation at the early stage of infection 
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and 1/3 developed diarrhea after fever. Additional studies looked 
at the intestine of volunteers to find S. typhi primarily infecting 
the ileum (the final portion of small intestine), particularly in the 
Peyer’s patches197,198. In the ileum, mucosal hypertrophy occurs 
due to mononuclear cells, with poor polymorphonuclear (PMN) 
cells infiltration. The fact that PMN cells are not abundantly 
found at the site of infection, underlines the capacity of S. typhi 
to exert a silent invasion compare to non-typhoidal strains or 
enterotoxigenic pathogens199. Low levels of septicemia are 
detected in most patients and it is thought to be required for the 
establishment of a systemic infection196.
S. enterica infection strategy
As S. typhi does not infect mice, S. typhimurium became 
the reference strain to study typhoid fever in rodents, as this 
pathogen recapitulates many of the characteristic of the human 
typhoid fever in susceptible mice196. S. enterica infects the host via 
ingestion of contaminated food or water. The bacterium survives 
the low pH level of the stomach200 and reaches the ileum where 
it preferentially cross the epithelial layer196. S. enterica employs 
flagella to penetrate the mucus, where it resists the numerous 
natural defenses of the host, such as IgA, digestive enzymes, bile 
salts and antimicrobial peptides201-203. Two different entry routes 
have been described to cross the epithelium monolayer: active 
endocytosis via enterocytes204 and pinocytosis of microfold (M) 
cells205 located on Peyer’s patches198. S. enterica is also able 
to disassemble the cellular tight junctions in vitro, thus adding 
another mechanism to facilitate pathogen penetration across the 
intestinal epithelium206. 
Although Salmonella preferentially invades the host through 
M-cell pinocytosis, data indicates that the capacity of Salmonella 
to invade and survive within epithelial cells is an essential feature 
Fig.11: S. typhi pathology in humans
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for its pathogenicity in vivo207. After crossing the intestinal barrier, 
Salmonella is pinocytosed by resident macrophages, where it 
survives and replicates within the Salmonella containing vacuole 
(SCV)208,209(Box.7).
To establish a successful infection, bacteria need to subvert 
the host cellular homeostasis and hijack cellular pathways to their 
advantage. S. enterica does so by injecting effectors directly into 
the cytoplasm of target cells. To deliver its effectors, Salmonella 
relays mostly on one organelle: the Type III Secretion System 
(T3SS). T3SS is a needle-like structure composed by a basal 
core that spans the bacterium periplasm, and an elongated 
part that injects proteins directly into the eukaryotic cell210. 
Secretion Systems are common among pathogenic bacteria, 
and are usually encoded in genetic island together with their 
secreted effectors. Salmonella encodes for two T3SS in distinct 
pathogenicity islands: SPI-1 and SPI-2. There are about 40 
virulence factors secretesd via SPI-1/2 T3SS characterized up to 
date207 and more then 300 have been predicted211. Both SPIs are 
essential for Salmonella pathogenicity and host colonization, but 
they exert different functions. 
SPI1-T3SS acts at the interface between the bacterium and 
cell and delivers its effectors through the plasma membrane. 
SPI1 is responsible for bacterial uptake into non-professional 
phagocytic cells, such as epithelial cells, to cause intestine 
inflammatory response, diarrhea and colonization. SPI-2-T3SS 
acts inside the SCV compartment, where it promotes survival 
and the establishment of a systemic infection207.
Inside the SCV, Salmonella changes the expression profile 
of more than 900 genes208, which help the bacterium to survive 
in this hostile compartment. SCV stimuli trigger the change in 
the LPS structure of the bacterium212, the modification of the 
peptidoglycans wall213, and the down-regulation of flagellin and 
SPI-1214. 
Of all SPI-2 effectors, SifA is essential for the maturation and 
integrity of this vacuolar compartment (Box.7b). Mutants for SifA 
show a cytoplasmic distribution, reduced intracellular replication 
and virulence215. SifA is injected to the outer-leaflet of the SCV, 
from where it mediates the formation of Salmonella-induced 
BOX.7: (A)
Salmonella enters 
the host via con-
taminated food 
or water. At the 
level of the ileum, 
it crosses the 
epithelial layer via 
M-cells and it is 
uptake by resident 
macrophages.
(B) Inside cells, 
Salmonella 
replicates within 
a vacuole, which 
homeostasis de-
pends on SifA and 
SKIP proteins.
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filaments (Sifs)216. Sifs are protuberances that grow along the 
microtubular cytoskeleton217,218. To produce Sifs, SifA binds to the 
host protein SKIP (SifA kinesin interacting protein) that connects 
the SCV to the microtubule motor kinesin. Additionally, the SifA 
carboxyl-terminus domain recruits members of the RHO small 
GTPase family to initiate endosomal tubulation219.
Chronic S. typhi infection
A significant percentage (1–6%) of people infected with S. typhi 
become chronic, asymptomatic carriers220. Since no other natural 
niches are known for S. typhi, chronic carriers serve as Salmonella 
natural reservoir, from whom the bacteria are periodically shed 
through feces221. In humans, S. typhi can establish an acute, 
active infection of the gallbladder, accompanied by inflammation 
(cholecystitis). The gallbladder is a small organelle of the liver, 
located above the duodenum, which aids fat digestion via the 
release of bile salts. S. typhi has been found in the gallbladder 
long after the end of the typhoid symptoms in patients, suggesting 
unique mechanisms used by S. typhi to mediate a long-term 
colonization in a hostile, bile-rich environment222.
The development of a chronic typhoid infection is frequently 
associated with the presence of gallbladder abnormalities, 
especially gallstones223. In typhoid endemic area, 5% of patients 
enrolled for gallbladder removal carry S. typhi as biofilm on 
gallstones224. In animal models, gallstones were shown to facilitate 
the formation of S. enterica biofilm, increasing colonization of the 
gallbladder and enhancing fecal shedding224. Although subjects 
who carry S. typhi often have biliary-tract disease, this condition 
is not an absolute requirement for the development of a carrier 
state220,225,226. In patients carrying both S. typhi and cholesterol 
gallstones in the gallbladder, antibiotics are typically ineffective 
against the bacterium223 and their risk for developing hepatobiliary 
carcinomas is higher than acutely infected patients 187,188.
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Today, no model that recapitulates Salmonella long-term infection and its role in cancer development has been 
established. Furthermore, the role of Typhoid Toxin in this 
process still remains to be elucidated. Here I present preliminary 
and unpublished data on a new animal model that we designed 
to address these issues.
Mice models of S. enterica infection
S. typhimurium is the standard pathogen to study typhoid 
infection in rodents. The classical animal model used for S. 
typhimurium infection and virulence tests are BALB/c and 
C57BL/6 mice (Fig.12). These strains are exquisitely sensitive to 
infection, and as little as 10 bacteria can cause death227. Signs 
of disease (i.e. elevated temperature) appear between 4–8 
days after oral inoculation, however, diarrhea does not develop. 
Intestinal inspections reveal enlarged Peyer’s patches and a 
thickening of the ileum mucosa. Diffuse enteritis is present in the 
small intestine characterized by a predominantly mononuclear 
infiltration228. Hyperplasia of the follicular area in the lymphoid 
tissue, capillary thrombosis, hemorrhage, and ulcerations may 
be present in the terminal ileum, while other areas of the intestine 
remain largely intact. The intestinal pathology and inflammatory 
reaction in mice is hence similar to that of typhoid fever patients197. 
S. Typhimurium in mice leads to a systemic bacterial 
dissemination. The rapid bacterial multiplication in the liver and 
spleen results in the hepatomegaly and splenomegaly229. Growth 
of bacteria in the mesenteric lymphnodes, the liver and the spleen 
triggers the formation of abscesses containing predominantly 
neutrophils. These microscopic lesions become enlarged and 
transform into granulomas, with central necrosis and peripheral 
mononuclear leukocytes230. In these lesions, Salmonella resides 
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within macrophages231. The granuloma observed in mice are 
similar to those present in tissues of chimpanzees infected with 
serovars Typhi232.
Contrary to BALB/c, the sv129 mouse strain is known to be 
resistant to S. typhimurium. This is due to the presence of a wild 
type version of the gene encoding for the natural-resistance-
associated macrophage protein 1 (NRAMP1), found inactive in 
both BALB/c and C57BL/6233. NRAMP1 is a macrophage-specific 
ion pump of the SCV, which restricts bacterial replication233-235. 
Monack et. al. showed that the sv129 mice can be infected with 
S. typhimurium, and that 108 bacteria per mouse still does not 
reach the LD50234. Despite the absence of fever, the animals 
bear S. typhimurium in mesenteric lymphnodes up to one year, 
and sporadically shed bacteria through feces.
Based on these data, we choose as animal model the sv129 
mice, and as bacterium the S. typhimurium strain MC71. Since 
S. typhimurium does not express the Typhoid Toxin, we cloned 
the TT operons into the chromosome of the MC71 strain by site 
directed recombination (MC71-CDT). Each subunit of the toxin 
was tagged with a different epitope for detection by Western-
blot or fluorescence microscopy. As control, we used an isogenic 
strain that lacks cdtB (MC71-∆cdtB).
The experimental set up consisted of three groups of mice: 
one group was left uninfected, one group was infected with the 
control MC71-∆cdtB strain, and one was infected with the strain 
expressing the active genotoxin (MC71-CDT) (Fig.13). Eight mice 
per group were sacrificed after 30 days, 60 days and 180 days 
post-infection (p.i.), and we collected the intestine, mesenteric 
MC71 is a S. 
typhimurium strain 
that carries a 
mutation within 
the phosphorylase 
(PNPase) gene, a 
general regulator 
of virulence. MC71 
shows a reduced 
virulence in vivo, 
and can establish 
long-term infection 
in BALB/c mice236
S. typhi in 
humans, without constipation, diarrhea, and establishment of a chronic carrier (indicated by the red 
crosses)
PRELIMINARY
DATA
Fig.12: S. typhimurium pathology in susceptible mice, which is similar to that induced by 
lymphnodes, liver and spleen to assess the bacterial load, while 
part of each tissue was preserved for histological examination 
and RNA extraction. Stools were also collected at the indicated 
time points for analysis of the intestinal microbiota.
Successful infection was determined by recovery of bacteria 
from the mesenteric lymphnodes, liver and spleen of all the 
infected mice 30 days and 60 days p.i., although the levels of 
bacteria recovery decreased of approximately 10 to 100 folds 
at 60 day p.i.. Salmonella was found only in the mesenteric 
lymphnodes in 40% of the mice 6 months p.i.. Differently from 
previous study234, we could not recover any bacterium from the 
gallbladder and this discrepancy may be due to the different 
bacterial strain used.
We found no differences in the infection burden of S. 
typhimurium between mice infected with the MC71-CDT and 
MC71-∆cdtB, indicating that the presence of the toxin does not 
influence colonization in this model. Other studies, however, 
have shown that CDT in H. hepaticus and C. jejuni seems to 
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Fig.
orally (p.o.) with 10^8 MC71-∆CdtB and MC71-CDT, for one, two and six months. Lower panel: 
animal weights in grams.
13: Schematic representation of sv129 chronic infection with MC71 strains. Mice were infected 
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facilitate colonization at 4 months p.i. in immune competent 
mice237,238. It is conceivable that this discrepancy is due to the 
different type of disease induced by these bacteria. H. hepaticus 
and C. jejuni cause a strong inflammatory response but do not 
spread systemically, while S. typhimurium causes a mild enteritis, 
followed by a rapid systemic infection.
From a histological point of view, we observed an enhanced 
inflammation of the liver in mice infected for 60 days, with 
the MC71-CDT strain compared to mice infected with the 
control MC71-ΔcdtB or uninfected mice. At 180 days p.i., the 
inflammation in the liver subsided, but we could observed a 
strong lymphatic hyperplasia in 4 out of 5 mice infected with the 
strain carrying the active genotoxin while this was not detected 
in any of the mice infected with the control strain. 
These data suggest that, although 180 days is not a sufficiently 
long period to detect any sign of pre-canceous/cancerous 
lesions in immunocompetent animals, the presence of typhoid 
toxin enhances the host pro-inflammatory response. This is 
supported by the preliminary data of the microbiota analysis, 
performed by High Taxonomy Fingerprint microbiota array239 
on the stool collected 7, 30 and 60 days p.i., which detected an 
enrichment of bacteria, such as Fusobacteriaceae, Bacteriaceae 
and Lactobacillaceae, associated with pro-inflammatory/pro-
carcinogenic environment240. We are currently analyzing the 
mRNA profile of the organs in infected and non infected mice 60 
days p.i. using GeneChip microarray, focusing on genes involved 
in DNA damage and host immune responses. We will further 
analyze the extent of oxidative damage in the relevant tissues.
 
The data, while promising, indicate that we would need to 
switch to a mouse model which is already prone to develop tumor. 
This will possibly allow us to consistently reduce the infection 
period. To address this issue, we have infected mice deficient 
for the tumor suppressor gene TAp73241. together with matching 
controls. Both strains have functional NRAMP1. The experiment 
is currently on going while writing this thesis.
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To demonstrate the importance of the choice of the model, the 
carcinogenic role of Colibactin in the development of colorectal 
cancer was recently demonstrated in germ free IL-10 knockout 
mice treated with the carcinogen azoxymethane (AOM)242. Mice 
mono-colonized with E. coli expressing Colibactin have higher 
incidence of adenocarcinoma than mice mono-colonised with a 
Colibactin-deficient E. coli242.
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Several interesting questions related to the Typhoid toxin remain to be elucidated. It is known that the toxin expression 
is induced once the bacterium is internalized and replicate 
inside the SCV of the infected cell12. However in order to reach 
the nucleus, the toxins has to be secreted from the producing 
bacterium and cross several cellular membranes. Therefore in 
paper III we have addressed these issues. For this study we 
used the S. typhimurium strain developed for the in vivo model 
described in the previous chapter. This bacterium has the 
additional advantage to be a lower risk pathogen compare to S. 
typhi, which matched our laboratory facility. We confirmed that 
the expression of all three toxin genes is induced in MC71-CDT 
in conditions that mimic the SCV in vitro, validating the model. 
Spano et. al. have previously shown that secretion of the 
toxin from the bacterium does not require the Salmonella SPI-2 
T3SS243, however all the there subunits present a signal sequence 
that direct their secretion into the periplasmic space244. Based on 
this evidence, we investigated whether the Typhoid Toxin was 
released from this location via outer-membrane vesicles (OMVs).
OMVs are spherical lipid bilayers that bud off the outer-
membrane (OM) of Gram-negative bacteria. OMVs have been 
found to be released also from Gram-positive bacteria280. Vesicles 
dimension span between 20 to 250 nm, and mass-spectrometry 
analysis indicates that OMVs are composed primarily by OM 
lipids and periplasmic proteins, ruling against bacterial lysis as 
responsible for their formation245. Moreover, OMVs generation 
does not result from a random budding of a bacterium surface, 
as only a selected portion of periplasmic proteins and LPS are 
found in the vesicles246,247. Ample evidence demonstrate that 
bacterial toxins, such as leukotoxin from Actionobacillus246, the 
heat-labile toxin from enterotoxigenic E.coli247 and anti-bacterial 
components released by Pseudomionas248, can be found in 
OMVs.
SECRETION 
OF TYPHOID TOXIN8
In paper III, we demonstrated that also TT is secreted within 
OMVs in conditions that mimic the SCV (in vitro) and in infected 
cells. Fluorescent and electron microscopy allowed the detection 
of OMVs within the SCV and in the cellular cytoplasm. Similar to 
our fundings, previous studies have demonstrated the presence 
of OMVs in the cytoplasm of Salmonella-infected cells249, and 
the PagK-family proteins were also reported to use OMVs to 
translocate into the cytoplasm of macrophages250.
Differential centrifugation of the culture medium confirmed 
that the toxin-loaded OMVs were released into the extracellular 
environment, and this process required an intact SCV, microtubule 
and actin cytoskeleton, indicating an active transport of OMVs 
toward the plasma membrane. Bacteria that are unable to form 
an intact vacuole, such as SifA mutants, did not secreted toxin-
loaded OMVs in the cellular medium. This is in agreement with 
previous data showing that SifA and its host interacting partner 
SKIP may promote the fission of vesicles from the SCV and their 
kinesin-1-dependent anterograde transport251. The importance 
of SifA and the formation of Sifs for Salmonella replication and 
virulence have been demonstrated in different models252, however 
up to date there are no factors secreted by Salmonella infected 
cells documented to use kinesin-1–dependent anterograde 
transport.
Once the toxin is released in OMVs from the infected cells, 
it has to be internalized by bystander cells to exert its genotoxic 
activity. We used dynamin-1 inhibitor to demonstrate active 
internalization of OMVs. Once internalized, the TT required an 
intact Golgi complex to exert intoxication, pointing to the OMVs 
retrotranslocation as possible trafficking pathway. A summary of 
these founding is depicted in Figure 14. 
The mechanisms by which OMVs deliver their content to cells 
were found to be different depending on the model bacterium. 
OMVs produced by A. actinomycetemcomitans fuse with 
cholesterol rich domains of the target cell membrane and release 
their content into the cytosol253. Conversely, Enterotoxigenic 
E. coli (ETEC) OMVs expose on the surface the heat-labile 
enterotoxin (LT), which mediates binding to the GM1 receptor in 
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important for Sal-
monella virulence
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caveolin-positive cholesterol domains247 and are endocytosed in 
a clathrin-independent manner254. H. pylori OMVs that carry the 
VacA toxin do not require lipid rafts for their internalization, while 
intoxication is partially clathrin-dependent255. 
Interestingly, the presence of bacterial toxins seems to 
enhance OMVs binding on cell membrane for ETEC and H. 
pylori. Though we did not perform a comparative analysis in our 
study, it is unlikely for TT to mediate OMVs binding as the toxin is 
hidden inside vesicles, differently from LT and VacA256.
Why OMVs?
The advantages for a bacterium to secret its effectors and 
toxins via OMVs are numerous, since this allow i) to deliver 
insoluble material; ii) to protect material from antibodies and 
proteinases; iii) to deliver high-concentration of the product.
Secretion of insoluble material
The P. aeruginosa quorum sensing proteins PQS257 are a 
group of highly hydrophobic peptides. PQS contributes to the 
resistance to UV irradiation, and synchronizes the entry of the 
bacterial population into the stationary phase258. PQS have be 
found to regulate their own package into secreting vesicles259. 
Fig.12:
Salmonella 
replicates within 
the SCV in the 
cytosol, from 
where it exploit the 
actin cytoskeleton 
to secret OMVs to 
the extracellular 
environment. 
OMVs are further 
uptake in cells 
following the 
endocytosis 
pathway.
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Adhesins are transmembrane proteins that mediate cell-to-
cell bacteria aggregation and facilitate colonization in tissue as 
biofilm formation. Porphyromonas gingivalis produces OMVs 
with adhesins, and these vesicles can induce cellular aggregation 
and aid the development of dental plaques260,261.
Protection from the environment
Soluble proteins are exposed to a variety of proteases and 
digestive enzymes present in niches colonized by the bacteria. 
Delivery of sensitive-effectors inside vesicles confers protection 
and may allow them to reach distant targets262,263. In our study, 
TT was found protected from trypsin digestion and antibody 
detection in OMVs secreted from infected cells.
High-concentration of delivered product 
OMVs can co-transport different molecules at the same time, 
increasing the delivery efficacy and favoring a synergic action. 
OMVs secreted by the Gram-positive bacteria Bacillus anthracis 
contain a ratio of 10:1 of anthrax toxin components protective 
factor (PA): lethal factor (LF)264.
OMVs in pathogenesis
Regardless their study in vitro, little evidence has been 
produced so far to indicate that OMVs are important mediator 
of bacterial pathogenesis.The primary reason is the lack of 
knowledge on the mechanisms that regulate OMVs shedding 
and the consequent inability to produce bacterial strains that 
lacks vesicles production. H. pylori can release OMVs following 
epithelial cell infection in vitro, and EM analysis found vesicles-
like structure in patients infected with H. pylori, indicating that 
they are produced in vivo265. The presence of OM proteins in the 
serum of rat during overwhelming E. coli infections might point 
to a possible role of OMVs during septic shock 266, and OMVs 
secreted by Borrelia burgdorferi were detected in the serum of 
human and dogs clinical samples as well as in experimentally 
infected mice267. 
In the context of bacteria-associated carcinogenesis, TT-loaded 
OMVs may have a double effect on the carcinogenic potential 
of Salmonella infection: i) efficient delivery of a genotoxic agent 
that causes DNA damage and may promote genomic instability, 
as shown for soluble CDT (paper II); ii) chronic activation of non 
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classical oncogene, such as NF-kB and STAT3268, mediated by 
the LPS and possibly other pathogen products may promote the 
survival of cells upon the genotoxic-dependent carcinogen hit.
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This thesis aimed to dissect the molecular mechanisms underling bacterial-induced carcinogenesis. I presented 
three works where we describe different aspects of the 
bacterial genotoxin known as Cytolethal Distending Toxin 
(CDT). Specifically, i) we identified a novel survival pathways 
triggered by acute CDT intoxication (paper I); ii) we described 
the molecular changes in response to chronic CDTs exposure 
in vitro (paper II) and set up of a new animal model to assess 
the carcinogenic potential of CDT-like-producing bacteria; and iii) 
we characterized a novel exocytosis-like process for paracrine 
delivery to the target cells of genotoxin-loaded vesicles produced 
by intracellular bacteria (paper III).
Numerous questions remain unanswered. The NET1-RHOA 
survival pathway triggered by cancer cells to delay/avoid 
apoptosis was partially expanded by the discovery that the FEN1 
is an important component in the activation of RHOA. It remains 
to elucidate whether FEN1 affects NET1 translocation to the 
cytoplasm, or activates RHOA in a NET1-independent manner. 
To accomplish this, we could deplete FEN1 with iRNA and 
look for NET1 translocation after DNA DSBs. Alternatively, we 
could express a tagged-NET1 in cells, and immuno-precipitate 
this protein before and after DNA damage to test whether it co-
precipitates with FEN1, thus suggesting a direct regulatory effect. 
Another important step would be to identify whether the catalytic 
activity of FEN1 is important for RHOA activation. To this end, we 
could expose FEN1-inactive MEFs to CDT269 and assess whether 
this would alter RHOA activation compare to MEFs expressing 
a functional protein. Ultimately, does NET1-RHOA play a role 
in cell survival of normal tissue, thus affecting carcinogenesis 
in vivo? Cell survival pathways can be significantly different 
between normal and cancer cells, as shown for the activity of 
Conclusions 
and future prospectives
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MAPKs p38 . Animal models where the dominant negative, or the 
constitutively active form of RHOA is placed under the control of 
a tetracyclin-inducible promoter may be instrumental to answer 
this question.
In the contest of cancer therapy, where genotoxic agents 
are delivered to cancer cells for a prolonged period of time, the 
study in paper II clarifies that cell lines can acquire a precise 
set of tumorigenic traits, if the DNA damage is not sufficient to 
trigger apoptosis. A recent article used genome sequencing data 
of acute myeloid leukemia before and after chemotherapy, and 
tracked the genetic changes of the relapsed disease270. It would 
be interesting to conduct a similar analysis on other solid tumors 
before and after the therapy, and specifically investigate whether 
genes that promote ROS, increase MAPKs p38 activity and 
alter the DDR would be found, thus proving these pathways as 
important players in vivo.
Our animal model will contribute to elucidate the function of 
typhoid toxin during chronic infections with typhoid strains. We 
would like to study where and when the toxin is actually produced 
in vivo, whether the toxin affects the genomic instability and the 
cancer progression during bacterial infection, and whether CDT 
could influence the immune response elicit against the pathogen.
I find particularly interesting the ability of Salmonella to reside 
inside macrophages and avoid killing. Most studies have looked 
at the mechanisms that this pathogen has developed to avoid 
lysosomal degradation or to quench nitric oxide within the SCV. 
In paper III, we found that Salmonella secretes vesicles to the 
extracellular environment via an exocytosis-like process. In the 
contest of an in vivo infection, where engulfed macrophages are 
surrounded by other cells, toxin secretion might prolong survival, 
by killing approaching effectors cells, like T lymphocytes. The use 
of in vitro models where infected macrophages are co-coltured 
with different subsets of T lymphocytes can be used to asses 
whether kinesin-1 secretion of components, and specifically TT 
secretion, promotes survival within macrophages via selective 
killing of the adaptive immunity effector cells.
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